Prolonged Treatment with Propofol Transiently Impairs Proliferation but Not Survival of Rat Neural Progenitor Cells In Vitro

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Palanisamy, Arvind, Matthew B. Friese, Emily Cotran, Ludde Moller, Justin D. Boyd, Gregory Crosby, and Deborah J. Culley. 2016. “Prolonged Treatment with Propofol Transiently Impairs Proliferation but Not Survival of Rat Neural Progenitor Cells In Vitro.” PLoS ONE 11 (7): e0158058. doi:10.1371/journal.pone.0158058. http://dx.doi.org/10.1371/journal.pone.0158058.

Published Version
doi:10.1371/journal.pone.0158058

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822097

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dashboard.current.terms-of-use#LAA
Prolonged Treatment with Propofol Transiently Impairs Proliferation but Not Survival of Rat Neural Progenitor Cells In Vitro

Arvind Palanisamy, Matthew B. Friese, Emily Cotran, Ludde Moller, Justin D. Boyd, Gregory Crosby, Deborah J. Culley

1 Department of Anesthesiology, Perioperative and Pain Medicine, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 2 Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden, 3 Laboratory for Drug Discovery in Neurodegeneration (LDDN), Harvard NeuroDiscovery Center, Harvard Medical School, Cambridge, Massachusetts, United States of America

These authors contributed equally to this work.

* apalanisamy@bwh.harvard.edu

Abstract

Neurocognitive dysfunction is common in survivors of intensive care. Prolonged sedation has been implicated but the mechanisms are unclear. Neurogenesis continues into adulthood and is implicated in learning. The neural progenitor cells (NPC) that drive neurogenesis have receptors for the major classes of sedatives used clinically, suggesting that interruption of neurogenesis may partly contribute to cognitive decline in ICU survivors. Using an in vitro system, we tested the hypothesis that prolonged exposure to propofol concentration- and duration-dependently kills or markedly decreases the proliferation of NPCs. NPCs isolated from embryonic day 14 Sprague-Dawley rat pups were exposed to 0, 2.5, or 5.0 μg/mL of propofol, concentrations consistent with deep clinical anesthesia, for either 4 or 24 hours. Cells were assayed for cell death and proliferation either immediately following propofol exposure or 24 hours later. NPC death and apoptosis were measured by propidium iodine staining and cleaved caspase-3 immunocytochemistry, respectively, while proliferation was measured by EdU incorporation. Staurosporine (1 μM for 6h) was used as a positive control for cell death. Cells were analyzed with unbiased high-throughput immunocytochemistry. There was no cell death at either concentration of propofol or duration of exposure. Neither concentration of propofol impaired NPC proliferation when exposure lasted 4 h, but when exposure lasted 24 h, propofol had an anti-proliferative effect at both concentrations (P < 0.0001; propofol vs. control). However, this effect was transient; proliferation returned to baseline 24 h after discontinuation of propofol (P = 0.37, propofol vs. control). The transient but reversible suppression of NPC proliferation, absence of cytotoxicity, and negligible effect on the neural stem cell pool pool suggest that propofol, even in concentrations used for clinical anesthesia, has limited impact on neural progenitor cell biology.
Introduction

Up to 30–50% of adult Intensive Care Unit (ICU) survivors suffer from long-term neurocognitive dysfunction, including impairment of attention, visual-spatial memory loss, and poor executive function, ultimately leading to long-lasting decreases in quality of life. [1–4] While there are undoubtedly numerous patient, disease, and treatment-related risk factors that predispose patients to the development of ICU cognitive impairment, the medications used for sedation have received a great deal of attention because they have profound CNS effects, are often administered for long periods, are implicated in neurotoxicity in some settings, and represent one of the few factors clinicians can readily modify. [3–9] Among these sedatives, gamma-amino butyric acid type A (GABA_A) agonists such as propofol enjoy considerable popularity. [5–7, 9, 10]

Formation of new memories requires generation of new neurons from neural progenitor cells (NPC) and the subsequent integration of these newborn neurons into pre-existing neural circuitry. [11–13] This neurogenesis is robust during development but persists into adulthood in a few areas of the brain such as the olfactory bulb and hippocampal dentate gyrus, a region critical for learning. [14–17] In preclinical studies, genetic ablation of neural progenitor cells in adults causes defects in learning and memory, indicating that a healthy cohort of NPCs is important for maintenance of cognitive health throughout life. GABA and glutamate are important molecular drivers of these processes [18–24] and as such, prolonged stimulation of GABA_A receptors, as occurs during ICU sedation, may have deleterious consequences. For example, we among others have found that isoflurane, a prototypical inhalational agent that potentiates GABA_A receptors, decreases proliferation of NPC in a concentration-dependent manner, and depletes the NPC pool without causing NPC death. [25–28] However, much less information is available for propofol, and the limited evidence that is available pertains to its short-term use in the operating room rather than the ICU. [29–31] In the latter setting, sedation rather than anesthesia is the goal, so medications are administered at sub-anesthetic doses over a much longer time period (> 24h).

Propofol, a GABA_A agonist, is one of the most widely used sedatives in the ICU. Preclinical studies regarding propofol’s effects on NPCs are conflicting, with propofol reportedly either increasing, decreasing, or having no effect on the proliferation of NPCs in vivo or in adult-derived NPCs in culture. [30, 32–36] This variability may be due to differences in experimental paradigms related to the route, concentration, and duration of administration of propofol, as well as differences in the method of quantification of NPC proliferation. Here, we hypothesize that prolonged exposure to propofol concentration- or duration-dependently kills or markedly decreases the proliferation of NPCs. Because adult and embryonic NPCs are qualitatively similar, [37] we tested this hypothesis in embryonic rat NPCs with concentrations of propofol consistent with deep anesthesia, administered for 4 and 24h, and evaluated the effect of such treatment on NPC proliferation and survival. We found no evidence for propofol-induced NPC toxicity or apoptosis. However, prolonged treatment with propofol caused a duration-of-exposure dependent suppression of NPC proliferation but this effect fully resolved within 24 h.

Materials and Methods

Neural Progenitor Cell Harvest and Culture

All animal experiments were approved by the Harvard Medical Area Standing Committee on Animals (Boston, MA). Neural stem/progenitor cells were harvested from timed pregnant embryonic day 14 Sprague Dawley rats (Harlan Sprague Dawley, Indianapolis, IN) as previously described. [25] The pregnant dam was euthanized with a 5-min exposure to 100% CO_2 prior to
isolation of the NPCs from embryonic telencephalons. No other inhalational agent was used for harvest. We isolated neural progenitor cells (NPCs) from 16 pregnant dams. NPCs from all embryos in a particular litter were pooled as one biological unit and subjected to experiments after the 2nd passage. We excluded 2 harvests because of suspected contamination. Each assay was repeated 3 times using independent biological samples from different dams, so each assay had N = 3 for biological replicates. NPCs were cultured in B27 medium which consists of Dulbecco’s Modified Eagle Medium/F12 high glucose (Invitrogen), supplemented with glutamine (1:200, Invitrogen), Fungizone® antimycotic (1:100, Invitrogen), penicillin-streptomycin (1:100, Invitrogen), B27 supplement without vitamin A (1:50, Invitrogen), and mitogenic growth factors FGF-2 and EGF (Peprotech) as previously described.[25] All experiments were performed 24 hours after the second passage to ensure consistency, which typically occurred on the 8th day in vitro (DIV). After the second passage, 10^4 NPCs in 100μl of medium was added to each well of a 96-well poly-L-ornithine/laminin coated microplates (BD BioCoat, BD Biosciences, San Jose, CA) using a multichannel pipette (Eppendorf, Westbury, NY), and placed in a humidified cell culture incubator at 37°C with 5% CO2 overnight prior to treatment.

Propofol Treatment

At the beginning of treatment, the medium from each well was removed and replaced with fresh B27 media containing 0.1% DMSO and 0 μg/mL (control), 2.5μg/mL, or 5.0μg/mL of propofol (2,6-diisopropylphenol, Acros Organics or Sigma-Aldrich). These concentrations were chosen to simulate predicted effect-site concentrations of propofol at loss of consciousness. [38–40] Furthermore, this concentration range is consistent with plasma propofol levels that are required to maintain sedation scores of 3–5 in mechanically ventilated patients. [41] NPCs were treated for either 4 or 24 hours, and were either fixed with 4% paraformaldehyde (PFA) at the end of treatment, or washed with phosphate-buffered saline (PBS) 5 times at the end of treatment, after which B27 media without propofol was added. The latter plates were placed in the incubator for 24 hours following which the NPCs were fixed with 4% PFA. Based on previous experience,[25, 42] we used 18 wells per treatment condition per time point for experiments to investigate cell death and proliferation as described below. NPCs from a single harvest were subjected to multiple experiments (cell death, EdU incorporation, cleaved caspase-3, etc.,) and experiments were repeated with NPCs from independent dams/harvests to generate a biological replicate of N = 3 per assay.

Propidium Iodide (PI) Staining. In plates assigned for quantification of cell death, 100μL of 1:100 propidium iodide (2mg/mL stock, Invitrogen) in B27 medium was added to each well after completion of treatment and allowed to incubate for 5 minutes prior to fixation with 4% PFA. We were unable to perform the lactate dehydrogenase (LDH) assay for cell death because of a significant concentration-dependent optical interaction with propofol.

EdU Incorporation Assay. Cell proliferation was determined with EdU incorporation using a commercially available kit according to the manufacturers’ instructions (Click-iT™ EdU Alexa Fluor® High-Throughput Imaging (HCS) Assay, Invitrogen) as described previously. [25] Briefly, 20μM EdU in 100μL of B27 medium with growth factors was added to 18 wells per treatment condition of a 96-well plate (number based on previous experience with the assay). The final concentration of EdU was 10μM in each well. For the 4h exposure paradigm, EdU was added at the same time as treatment with propofol, but for the 24h group, EdU was added during the last 4 hours of treatment. This was necessary because of the length of the S-phase of the rodent NPC cycle. In the propofol withdrawal experiments, EdU was added during the last 4 h of the 24 h after treatment was discontinued (i.e., at 20 h after conclusion of treatment). NPCs were then fixed with 4% PFA in PBS for 15 minutes at which time the fixative was
removed and the cells washed twice with 250 μL PBS using an automated plate washer (Molecular Devices), and incubated in 100 μL of 0.5% Triton X-100 in PBS for 20 min at room temperature. The cells were then washed twice and incubated with 100 μL Click-iT reaction cocktail for 30 minutes at room temperature. The reaction cocktail was removed and the cells were washed twice with PBS and stored until fluorescence immunocytochemistry was performed for nestin, followed by staining with Hoechst 33342 to detect and label all nuclei to facilitate total cell counts. The nuclear intensity threshold for an EdU positive cell was defined by the intensity of EdU reactivity in NPCs from control wells.

**Immunocytochemistry.** After the EdU incorporation assay, cells were washed three times with PBS, and blocked with 100 μL/well 3% BSA in PBS for 1 hour at room temperature followed by incubation with the primary antibodies nestin (Millipore, Billerica, MA, 1:500 dilution) and cleaved caspase-3 (CC3, Abcam Inc., Cambridge, MA, 1:500 dilution) overnight at 4°C. Nestin is widely used as a marker for stemness while CC3 is a marker of early apoptosis. The wells were then washed 3 times with PBS and species-matched secondary antibody (Alexa Fluor 488 or Alexa Fluor 555, 1:200, Invitrogen) was applied and incubated for 1 hour at room temperature. The wells were washed 3 times and then incubated with 100 μL of 5 μg/mL Hoechst 33342 in PBS for 30 minutes at room temperature, washed three times with PBS, and stored in the dark at 4°C until image acquisition and analysis. NPCs treated with 1 μM staurosponine for 6 hours served as a positive control for CC3 experiments. For PI and CC3 experiments, a nuclear/cellular intensity ratio greater than 2 or 2.5 indicated cell death or apoptosis, respectively.

**Image Acquisition and Analysis**

**Image Acquisition.** Eight images (number based on previous experience with this system) were acquired per well using an IN Cell Analyzer 1000 (GE Healthcare, Piscataway, NJ) in an automated unbiased fashion as described previously. Because image acquisition is automated and large numbers of images can be acquired, cell selection bias is eliminated and the impact of experimental and biological variation is reduced. The parameters used for cellular identification were identical to those reported in our previous study with isoflurane.[25] For identification and analysis of EdU, PI and CC3 positive cells, we used a two-step filtering process. In the first step, nestin-negative cells were excluded; in the second, threshold setting was used to determine the number of EdU, PI, and CC3 positive cells. Thus, only nestin-reactive cells were analyzed and included in the final analysis. Imaging parameters were set based on the control wells stained with the fluorophore or antibody of interest and the parameters used to image all treated wells on the plate. In these experiments, 8 images were acquired per well with a 20X objective from 12–18 wells per treatment condition per assay per time. All experiments were repeated in at least three biologically independent NPC cultures.

**Statistical Analysis.** Data from each assay that passed equal variance testing were analyzed using 1-way ANOVA followed by Dunnett’s multiple comparison tests against control treatment at each time point. Data that did not pass equal variance testing were analyzed with Kruskal-Wallis 1-way ANOVA followed by Dunn’s testing for multiple comparisons. Data analysis was performed using Prism 5 for MAC OS X (Graphpad Software, Inc, La Jolla, CA) software and expressed as mean ± S.E.M; P ≤ 0.05 was accorded statistical significance.

**Results**

Over 96% of control cells plated on poly-L-ornithine/laminin coated plates were immunoreactive for nestin at the end of treatment and 24 h later, confirming the purity of NPC culture (Fig 1).
Propofol Does Not Cause NPC Death

PI is a cell impermeable dye that labels DNA only when cellular integrity is compromised and is widely used to measure of cell viability. There were few dead or dying cells, as determined by PI staining, at any time under control conditions (< 2%; Fig 2), indicating that the cultures were healthy. Similarly, there was no effect of propofol treatment (both 4 and 24 h) on the percentage of cells that stained positive for PI at the end of treatment (P = 0.08 and 0.32, respectively; Fig 3) or 24 h after treatment (P = 0.52 and 0.45, respectively; Fig 4).

Propofol Does Not Induce NPC Apoptosis

Cleaved caspase-3 is a critical component of apoptosis and is a marker for programmed cell death. Few cells stained positive for cleaved caspase-3 under control conditions (< 2%) and there was no effect of 4 or 24 h of propofol treatment on the percentage of cells staining positive for cleaved caspase-3 at the end of treatment (P = 0.51 and 0.14, respectively; Fig 5). 24 h after withdrawal, there were no differences in cleaved caspase-3 expression in the group that was treated with either 4 or 24 h of propofol (P = 0.61 and 0.24, respectively; Fig 6). Collectively, these data indicate that propofol has no cytotoxic effect on NPCs at the concentrations tested.

Prolonged Treatment with Propofol Transiently Impairs Proliferation of NPCs

Cell proliferation was determined with EdU incorporation. Like BrdU, EdU is a thymidine analogue that incorporates into actively mitotic cells during the S-phase of cell division and is...
widely used to assess cell proliferation [43]. The advantage of EdU is that it eliminates the need for the heating step associated with BrdU immunohistochemistry. Propofol impaired proliferation of NPCs in a duration of exposure-dependent manner as revealed by decreased EdU incorporation. With 4 h of treatment, both 2.5 and 5.0 μg/mL of propofol did not affect EdU incorporation in NPCs suggesting that 4 h of propofol exposure does not alter NPC proliferation in vitro (P = 0.13; Fig 7A). However, with 24 h of propofol treatment, both concentrations significantly reduced EdU incorporation compared to control treatment (P < 0.0001 for propofol vs. control; Fig 7B). Representative 20x photomicrographs from control and propofol-treated wells are shown in Fig 8.

To determine if these effects were transient, we studied EdU incorporation at 24 h following withdrawal of propofol in a separate set of experiments. After 24 h, there was no evidence of impaired EdU incorporation at either concentration of propofol (2.5 and 5.0 μg/ml) after either
duration of treatment (4 h and 24 h; Fig 9A and 9B, respectively). These data collectively suggest that propofol transiently impairs NPC proliferation in a duration of exposure-dependent manner.

Prolonged Treatment with Propofol Does Not Decrease Neural Progenitor/ Stem Cell Pool

Because we found a 7–14% overall decrease in the neural stem cell pool 24 h after isoflurane treatment,[25] we asked the question if propofol would induce a similar effect. To investigate this, we quantified the overall proportion of NPCs expressing the stemness marker nestin 24 h after propofol treatment (2.5 or 5.0 μg/mL for 24 h). There was no change in the overall

Fig 3. No difference in NPC death at the end of propofol treatment. A bar graph showing the proportion of dead NPCs in wells treated with 2.5 or 5 μg/mL of propofol for either 4 or 24 h as noted. Cell death was quantified with PI staining. There were no differences in NPC death at both concentrations compared to control treatment either at 4 or at 24 h. Data are presented as mean ± S.E.M and expressed as percent of the control value (N = 3 per condition; P = 0.08 and 0.32 at 4 and 24 h with Kruskal-Wallis test and 1-way ANOVA, respectively). doi:10.1371/journal.pone.0158058.g003

Fig 4. No difference in NPC death 24 h after discontinuation of propofol treatment. A bar graph showing the proportion of dead NPCs in wells treated with either 2.5 or 5 μg/mL of propofol, 24 h after discontinuation of treatment as noted. Cell death was quantified with PI staining. There were no differences in NPC death at both concentrations compared to control treatment 24 h after discontinuation of propofol. Data are presented as mean ± S.E.M and expressed as percent of the control value (N = 3 per condition; P = 0.52 and 0.45 for the 4 and 24 h treatment groups, respectively, with 1-way ANOVA). doi:10.1371/journal.pone.0158058.g004
The proportion of nestin positive NPCs 24 h after both concentrations of propofol compared to control treatment (Fig 10). This suggests that, unlike isoflurane, propofol does not decrease the neural stem cell pool.

Discussion

In this in vitro study, we present evidence that propofol impairs rodent NPC proliferation in a duration of exposure-dependent manner without affecting the viability of NPCs. Specifically, we found that treating NPCs with 2.5 or 5.0 μg/mL for 24 hours transiently impairs NPC proliferation which normalizes within 24 hours. Moreover, both concentrations of propofol had no effect on NPC survival at any time point. Finally, we also confirm that propofol treatment...
was not accompanied by a reduction in the overall neural stem cell pool. These findings contrast with our studies using isoflurane where the effect of treatment with isoflurane administered at or above 1 MAC concentration administered for 6 h lead to impaired NPC proliferation even 24 hours later with a reduction in the neural stem cell pool.\[25\] To our knowledge, this is the first in vitro study to investigate the impact of propofol on NPCs within the context of the concentration and duration of exposure ranges commonly observed in ICU practice.

![Fig 7. 24 h of propofol treatment impairs NPC proliferation.](image1)

A bar graph showing the proportion of proliferating NPCs in wells treated with 2.5 or 5 μg/mL of propofol for either 4 or 24 h. Proliferation was quantified with EdU immunocytochemistry. There were no differences in NPC proliferation at 4 h compared to control treatment (Fig 7A). However, both concentrations of propofol significantly decreased NPC proliferation in the 24 h treatment group (Fig 7B). Data are presented as mean ± S.E.M and expressed as percent of the control value (N = 3 per condition; P = 0.13 and < 0.0001 at 4 and 24 h, with Kruskal-Wallis test and 1-way ANOVA respectively); ** P ≤ 0.01 and *** P ≤ 0.001.

doi:10.1371/journal.pone.0158058.g007

![Fig 8. Effect of propofol on EdU incorporation at 24 h.](image2)

Representative 20x photomicrographs of control (Fig 8A) and propofol-treated (Fig 8B) NPCs stained with nestin (red). 24 h of treatment with propofol causes a decrease in the number of NPCs that incorporate EdU (green) compared to control. Scale bar as noted.

doi:10.1371/journal.pone.0158058.g008
Previous studies have focused on the effects of propofol administered during synaptogenesis, the phase of active brain growth during early development. Specifically, propofol administration was associated with robust neurodegeneration only in postnatal day 7–10 (PND 7–10) pups, but not at PND 14 or beyond, suggesting that the effect is developmental time-sensitive. Since synapse pruning and sculpting of neural circuits are largely completed during adolescence, these studies are less helpful in understanding the effects of propofol on the mature brain. Neurogenesis does continue in the mature brain, however, and multiple neurogenic niches exist in the subventricular zone, the subgranular zone, and the dentate gyrus. These niches contain NPCs that proliferate, migrate, and integrate into pre-existing neural

![Fig 9. Propofol induced inhibition of NPC proliferation resolves within 24 h. A bar graph showing the proportion of proliferating NPCs 24 h after treatment with 2.5 or 5 μg/mL of propofol for either 4 or 24 h. Proliferation was quantified with EdU immunocytochemistry. There were no differences in NPC proliferation 24 h after treatment with both concentrations as measured by EdU incorporation. Data are presented as mean ± S.E.M and expressed as percent of the control value (N = 3 per condition; P = 0.21 and 0.38 for the 4 and 24 h treatment groups, respectively, with 1-way ANOVA).](#)

doi:10.1371/journal.pone.0158058.g009

![Fig 10. Prolonged treatment with propofol does not decrease the neural stem cell pool. A bar graph showing the proportion of NPCs 24 h after treatment with either 2.5 or 5 μg/mL of propofol for 24 h. NPCs were phenotyped with nestin immunocytochemistry. There were no differences in the overall proportion of nestin-positive NPCs 24 h after treatment with both concentrations. Data are presented as mean ± S.E.M and expressed as percent of the control value (N = 3 per condition; P = 0.67 with Kruskal-Wallis test).](#)

doi:10.1371/journal.pone.0158058.g010
circuits and play a large role in consolidation of learning, memory, and visual-spatial orientation.\cite{11-15, 26, 46, 47} Because propofol is widely used for sedation in mechanically ventilated patients, it raises the interesting question if prolonged exposure to propofol at sub-anesthetic concentrations, as is typical for ICU sedation, affects NPC biology to the extent that it impairs cognitive function.

To begin to address this question, we sought to determine the effect of propofol on proliferation of NPCs at two different concentrations (2.5 and 5.0 μg/mL) and durations (4 and 24h). These concentrations of propofol were chosen after careful consideration of the predicted effect-site concentration of propofol at loss of consciousness.\cite{38, 41, 48} We found that both 2.5 and 5.0 μg/mL of propofol inhibited NPC proliferation when administered for 24 h. The finding of decreased NPC proliferation after 24 h of propofol is consistent with the findings of Liu et al., \cite{23} suggesting that the duration of propofol treatment is a critically important factor when clinically relevant concentrations are tested. More importantly, we confirmed that the impaired proliferation of NPCs is transient, because there was no change in EdU incorporation at 24 hours after discontinuation of propofol.

There was no evidence for NPC death at either concentration of propofol at any time point. This finding contrasts with other in vitro studies suggesting that propofol induces apoptosis and causes cell death in NPCs.\cite{34-36} These differences can be readily reconciled when the concentrations of propofol are taken into consideration. Propofol-induced NPC apoptosis occurred only at supraclinical concentrations, i.e., 50 μM or higher, which is equivalent to approximately 8.9 μg/mL or greater (molecular weight of propofol = 178 g/mol). Pharmacokinetic studies with propofol show a consistent concentration-effect response with a plasma propofol concentration of 1.5–2.0 μg/mL correlating with deep sedation and 4.0–5.0 μg/mL correlating with general anesthesia, at least in adult humans.\cite{40, 41, 49} For our experiments, we settled on the upper limit of the concentration range, i.e., 5.0 μg/ml of propofol. Our choice of 4 and 24 hours of propofol treatment to mirror total intravenous anesthesia and critical care sedation, respectively, was arbitrary but well within the acceptable range of clinical practice. Indeed, Sall et al. did not find evidence for NPC toxicity at a propofol concentration of < 7.1 μM (equivalent to ≈ 1.2 μg/mL).\cite{50} Therefore, concentration is probably an important determinant of propofol neurotoxicity, with concentrations ≤ 5.0 μg/mL being unlikely to have any significant impact on NPC survival. The lack of cytotoxic effect of propofol is in contrast to the effect of propofol on immature neurons, where in vitro and in vivo studies show caspase activation and neuronal death.\cite{51-54} We speculate this is because NPCs are at a relatively more primordial stage of development; they have GABA\textsubscript{A} receptors \cite{50} but may lack the full range of membrane receptors and subcellular signaling mechanisms that make immature neurons vulnerable to pharmacologic insults. Along these lines, isoflurane, which causes a 20–30% decrease in NPC proliferation,\cite{25} does not kill NPCs, and ketamine, at a wide range of concentrations, likewise impairs NPC proliferation without causing cell death.\cite{55} Thus, whatever the mechanism, NPCs appear to be inherently more resistant to pharmacological insults than immature neurons. Finally, prolonged treatment with propofol did not decrease the overall pool of NPCs. This contrasts with preclinical studies that show a decrease in the neural stem cell pool with isoflurane.\cite{25, 28} We speculate that this is perhaps due to the modest and transient suppression of NPC proliferation, or due to differences in the mechanism of action between propofol and isoflurane \cite{56, 57}.

Our results are generally concordant with preclinical and clinical studies that have examined the effect of propofol on cognitive function, particularly in the adult brain. For example, a 2 h of propofol anesthesia in aged rodents (18 month old) does not affect hippocampus-dependent spatial memory,\cite{58} and nor does a 3 h propofol anesthetic affect olfactory learning in 21-month-old aged rats.\cite{30} Both the dentate gyrus of the hippocampus and the olfactory
bulb are sites of robust adult neurogenesis.[59–61] In fact, in the multicenter BRAIN-ICU trial, sedation with benzodiazepines, but not propofol, was associated with impaired executive function 3 months later, though neither agent influenced global cognition scores.[3] This suggests that propofol is free of the significant long-term neurocognitive consequences that have been reported with other GABA_A agonists such as isoflurane, [62] perhaps in part because it does not diminish the pool of neural progenitor cells.

Our study is limited in some ways. First, as we had previously reported, EdU is a thymidine analogue that is incorporated into DNA only during the S-phase of cell division. Therefore, it is possible that we missed subtle alterations in the other phases of the cell cycle. Second, we arbitrarily chose to study the effects of propofol withdrawal after 24 h and therefore, it is possible that we may have missed immediate changes. However, the finding that the suppression of NPC proliferation is transient and resolves within 24 h argues against a toxic effect. Third, because critically ill patients are usually sedated with other agents in addition to propofol, we do not know whether a combination of such agents will have a more pronounced effect on NPC biology. Further, biological systems are inherently complex, so our in vitro results should be interpreted cautiously as multiple factors are likely to influence NPC biology in vivo, and studies show that mild, functional impairment can occur with propofol treatment via mechanisms unrelated to NPCs. In addition, we are unable to comment on the effect of propofol on NPCs beyond 24 h, a duration that is not uncommon during intensive care unit sedation. Finally, there is some uncertainty about the in vitro concentration of propofol that emulate those achieved clinically during sedation and anesthesia. This is because clinical studies typically measure blood concentrations of propofol, which may not accurately predict the concentration of the free, unbound, pharmacologically active fraction, and use multi-compartment mathematical models to calculate effect site concentrations that might not be relevant to single compartment in vitro studies. However, a rat microdialysis study showed that the free, unbound concentration of propofol in the brain interstitial fluid is approximately 50–60% of the measured total plasma level after a continuous infusion.[63, 64] This suggests the propofol concentrations and exposure conditions we used are clinically relevant, and that even concentrations consistent with deep propofol general anesthesia are without long term effects on NPC fate.

Conclusions
In summary, our results demonstrate that propofol has 1) no effect on NPC survival in vitro; 2) no effect on NPC proliferation when exposure is limited to 4 h; and 3) an anti-proliferative effect when exposure lasts 24 h that fully resolves by 24 h after exposure. This suggests that prolonged treatment with propofol is unlikely to diminish the neural progenitor pool in vivo and that loss of neural progenitors is unlikely to explain neurocognitive dysfunction in ICU survivors sedated with this medication. However, whether propofol affects neurogenesis or cell fate selection remains to be determined.

Supporting Information
S1 Dataset.
(PZF)

Acknowledgments
The authors thank Marcie A. Glicksman, PhD, Director, Leads Discovery, Laboratory for Drug Discovery in Neurodegeneration (LDDN), Harvard NeuroDiscovery Center, Harvard Medical School, Brigham & Women’s Hospital, Cambridge, MA for her helpful comments and advice.
on high-content screening. The work was supported by NIH GM088817 to GC. MBF was supported by a NIH T32 training grant (5T32GM007592) to the Harvard Medical School Department of Anesthesia

Author Contributions
Conceived and designed the experiments: DC AP MF GC. Performed the experiments: DC AP LM EC JB MF. Analyzed the data: DC AP. Contributed reagents/materials/analysis tools: JB. Wrote the paper: AP DC GC MF.

References
1. Woon FL, Dunn CB, Hopkins RO. Predicting cognitive sequelae in survivors of critical illness with cognitive screening tests. Am J Respir Crit Care Med. 2012;186(4):333–40. doi: 10.1164/rccm.201112-2261OC PMID: 22700858.
2. Hopkins RO, Suchyta MR, Farrer TJ, Needham D. Improving post-intensive care unit neuropsychiatric outcomes: understanding cognitive effects of physical activity. Am J Respir Crit Care Med. 2012;186(12):1220–8. doi: 10.1164/rccm.201206-1022OP PMID: 23065913.
3. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-term cognitive impairment after critical illness. The New England journal of medicine. 2013;369(14):1306–16. doi: 10.1056/NEJMoa1301372 PMID: 24088902; PubMed Central PMCID: PMC3922401.
4. Gunther ML, Jackson JC, Ely EW. The cognitive consequences of critical illness: practical recommendations for screening and assessment. Critical care clinics. 2007;23(3):491–506. doi: 10.1016/j.ccc.2007.07.001 PMID: 17900482.
5. Hughes CG, Pandharipande PP. Review articles: the effects of perioperative and intensive care unit sedation on brain organ dysfunction. Anesth Analg. 2011;112(5):1212–7. Epub 2011/04/09. ANE.0b013e318215366d [pii] doi:10.1213/ANE.0b013e318215366d PMID: 21474859.
6. Patel SB, Kress JP. Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med. 2012;185(5):486–97. Epub 2011/10/22. 201102-0273CI [pii] doi:10.1164/rccm.201102-0273CI PMID: 22016443.
7. Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med. 2009;37(12):3031–9. Epub 2009/07/28. doi:10.1097/CCM.0b013e3181b02eef PMID: 19633543.
8. Girard TD, Jackson JC, Pandharipande PP, Pun BT, Thompson JL, Shintani AK, et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med. 2010;38(7):1513–20. Epub 2010/05/18. doi:10.1097/CCM.0b013e3181e47be1 PMID: 20473146.
9. Lonardo NW, Mone MC, Nirula R, Kimball EJ, Ludwig K, Zhou X, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilator-dependent critical care unit patients. Am J Respir Crit Care Med. 2014;189(11):1383–94. Epub 2014/05/29. doi:10.1164/rccm.201312-2291OC PMID: 24720509.
10. Djaiani G, Silverton N, Fedorko L, Carroll J, Styra R, Rao V, et al. Dexmedetomidine versus Propofol Sedation Reduces Delirium after Cardiac Surgery: A Randomized Controlled Trial. Anesthesiology. 2015. doi:10.1097/ALN.0000000000000951 PMID: 26575144.
11. Aimone JB, Deng W, Gage FH. Resolving new memories: a critical look at the dentate gyrus, adult neurogenesis, and pattern separation. Neuron. 2011;70(4):589–96. Epub 2011/05/26. S0896-6273(11)00391-6 [pii] doi:10.1016/j.neuron.2011.05.010 PMID: 21609818.
12. Marin-Burgin A, Schinder AF. Requirement of adult-born neurons for hippocampus-dependent learning. Behav Brain Res. 2011;227(2):391–9. Epub 2011/07/19. S0166-4328(11)00509-2 [pii] doi:10.1016/j.bbr.2011.07.001 PMID: 21763727.
13. Vivar C, van Praag H. Functional circuits of new neurons in the dentate gyrus. Frontiers in neural circuits. 2013;7:15. doi: 10.3389/fncir.2013.00015 PMID: 23443839; PubMed Central PMCID: PMC3580993.
14. Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011;70(4):687–702. Epub 2011/05/26. S0896-6273(11)00348-5 [pii] doi: 10.1016/neuron.2011.05.001 PMID: 21609825.
15. Mongiat LA, Schinder AF. Adult neurogenesis and the plasticity of the dentate gyrus network. Eur J Neurosci. 2011;33(6):1055–61. doi:10.1111/j.1460-9568.2011.07603.x PMID: 21395848.
16. Kempermann G. Activity Dependency and Aging in the Regulation of Adult Neurogenesis. Cold Spring Harbor perspectives in biology. 2015;7(11). doi: 10.1101/cshperspect.a018929 PMID: 26525149.
17. Feliciano DM, Bordey A, Bonfanti L. Noncanonical Sites of Adult Neurogenesis in the Mammalian Brain. Cold Spring Harbor perspectives in biology. 2015; 7(10). doi: 10.1101/cshperspect.a018846 PMID: 26384869.

18. Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci. 2002; 3(9):728–39. Epub 2002/09/05. doi: 10.1038/nrn920 nm920 [pii]. PMID: 12209121.

19. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev. 2007; 87(4):1215–84. Epub 2007/10/12. 87/4/1215 [pii] doi: 10.1152/physrev.00017.2006 PMID: 17928584.

20. Li Y, Aimone JB, Xu X, Callaway EM, Gage FH. Development of GABAergic inputs controls the contribution of maturing neurons to the adult hippocampal network. Proc Natl Acad Sci U S A. 2012; 109 (11):4290–5. Epub 2012/03/01. 1120754109 [pii] doi: 10.1073/pnas.1120754109 PMID: 22371596.

21. LoTurco JJ, Owens DF, Heath MJ, Davis MB, Kriegstein AR. Propofol and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis. Neuron. 1995; 15(6):1287–98. Epub 1995/12/01. 0896-6273(95)90008-X [pii]. PMID: 8454153.

22. Wang DD, Kriegstein AR. Defining the role of GABA in cortical development. J Physiol. 2009; 587(Pt 1):1873–9. Epub 2009/01/21. jphysiol.2008.167635 [pii] doi: 10.1113/jphysiol.2008.167635 PMID: 19153158.

23. Encinas JM, Sierra A. Neuronal stem cell deoxygenation as the main force driving the age-related decline in adult hippocampal neurogenesis. Behav Brain Res. 2011 227(2):433–9. Epub 2011/10/25. S0166-4328(11)00728-5 [pii] doi: 10.1016/j.bbr.2011.10.010 PMID: 2209362.

24. Pallotto M, Deprez F. Regulation of adult neurogenesis by GABAergic transmission: signaling beyond GABAA-receptors. Frontiers in cellular neuroscience. 2014; 8:166. doi: 10.3389/fncel.2014.00166 PMID: 24999317; PubMed Central PMCID: PMC4064292.

25. Culley DJ, Boyd JD, Palanisamy A, Xie Z, Kojima K, Vacanti CA, et al. Isoflurane decreases self-renewal capacity of rat cultured neural stem cells. Anesthesiology. 2011; 115(4):754–63. Epub 2011/ 06/15. doi: 10.1097/ALN.0b013e318223b7eb PMID: 21666433.

26. Stratmann G, Sall JW, May LD, Bell JS, Magnusson KR, Rau V, et al. Isoflurane differentially affects neurogenesis and long-term neurocognitive function in 60-day-old and 7-day-old rats. Anesthesiology. 2009; 110(4):834–48. Epub 2009/03/19. doi: 10.1097/ALN.0b013e31819c463d PMID: 19293705.

27. Sall JW, Stratmann G, Leong J, McKleroy W, Mason D, Shenoy S, et al. Isoflurane inhibits growth but does not cause cell death in hippocampal neural precursor cells grown in culture. Anesthesiology. 2009; 110(4):826–33. Epub 2009/03/19. doi: 10.1097/ALN.0b013e31819b62e2 PMID: 19293697.

28. Zhu C, Gao J, Karlsson N, Li Q, Zhang Y, Huang Z, et al. Isoflurane induced an imbalance of neural progenitor cells and reduced neurogenesis in young, but not adult, rodents. J Cereb Blood Flow Metab. 2010; 30(5):1017–9. Epub 2010/01/14. jcbfm2009274 [pii] doi: 10.1038/jcbfm.2009.274 PMID: 20068576.

29. Creeley C, Dikranian K, Dissen G, Martin L, Olney J, Brambrink A. Propofol-induced apoptosis of neurons and oligodenodrocytes in fetal and neonatal rhesus macaque brain. Br J Anaesth. 2013; 110 Suppl 1:i29–38. doi: 10.1093/bja/aet173 PMID: 23722059; PubMed Central PMCID: PMC3667437.

30. Eraso DM, Chaparro RE, Quiroga Del Rio CE, Karlnoski R, Camporesi EM, Saporta S. Quantitative assessment of new cell proliferation in the dentate gyrus and learning after isoflurane or propofol anesthesia in young and aged rats. Brain research. 2012; 1441:38–65. doi: 10.1016/j.brainres.2011.11.025 PMID: 22297171.

31. Krzisch M, Soltan S, Sandell J, Demeter K, Vutskits L, Toni N. Propofol anesthesia impairs the maturation and survival of adult-born hippocampal neurons. Anesthesiology. 2013; 118(3):602–10. doi: 10.1097/ALN.0b013e3182815948 PMID: 23314165.

32. Eraso DM, Camporesi EM, Mangar D, Saporta S. Effects of isoflurane or propofol on postnatal hippocampal neurogenesis in young and aged rats. Brain research. 2013; 1530:1–12. doi: 10.1016/j.brainres.2013.07.035 PMID: 23891717.

33. Tao T, Zhao Z, Hao L, Gu M, Chen L, Tang J. Propofol promotes proliferation of cultured adult rat hippocampal neural stem cells. J Neurosurgery Anesthesiology. 2013; 25(3):299–305. doi: 10.1097/ANA. 0b013e3182baa93 PMID: 23519370.

34. Wang JW, Cheng WW, Xu T, Yang ZY. Propofol induces apoptosis and inhibits the proliferation of rat embryonic neural stem cells via gamma-aminobutyric acid type A receptor. Genetics and molecular research; GMR. 2015; 14(4):4920–8. doi: 10.4238/2015.November.18.57 PMID: 26600553.

35. Liu F, Rainosek SW, Sadovnova N, Fogle CM, Patterson TA, Hanig JP, et al. Protective effect of acetyl-L-carnitine on propofol-induced toxicity in embryonic neural stem cells. Neurotoxicology. 2014; 42:49–57. doi: 10.1016/j.neuro.2014.03.011 PMID: 24704589.
48. Masica AL, Girard TD, Wilkinson GR, Thomason JW, Truman Pun B, Nair UB, et al. Clinical sedation
Sall JW, Stratmann G, Leong J, Woodward E, Bickler PE. Propofol at clinically relevant concentrations
50. Casati A, Fanelli G, Casaletti E, Cedrati V, Veglia F, Torri G. The target plasma concentration of propo-
52. Pearn ML, Hu Y, Niesman IR, Patel HH, Drummond JC, Roth DM, et al. Propofol neurotoxicity is medi-
51. Spahr-Schopfer I, Vutskits L, Toni N, Buchs PA, Parisi L, Muller D. Differential neurotoxic effects of pro-
53. Zhong Y, Liang Y, Chen J, Li L, Qin Y, Guan E, et al. Propofol inhibits proliferation and induces neuroa-
36. Chehrehasa F, Meedeniya AC, Dwyer P, Abrahamsen G, Mackay-Sim A. EdU, a new thymidine ana-
44. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-
46. Spahr-Schopfer I, Vutskits L, Toni N, Buchs PA, Parisi L, Muller D. Differential neurotoxic effects of pro-
37. Merkle FT, Alvarez-Buylla A. Neural stem cells in mammalian development. Current opinion in cell biol-
50. Iwakiri H, Nishihara N, Nagata O, Matsukawa T, Ozaki M, Sessler DI. Individual effect-site concentra-
42. Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, et al. Propofol dosing regimens
41. Fredriksson A, Cotran EK, Karlsson E, Palanisamy A, Boyd JD, Xie Z, et al. Isoflurane affects the cytoske-
40. Rigouzzo A, Girault L, Louvet N, Servin F, De-Smet T, Piat V, et al. The relationship between bispectral
38. Iwakiri H, Nishihara N, Nagata O, Matsukawa T, Ozaki M, Sessler DI. Individual effect-site concentra-
39. Fiset P, Paus T, Daloze T, Plourde G, Meuret P, Bonhomme V, et al. Brain mechanisms of propofol-
37. Merkle FT, Alvarez-Buylla A. Neural stem cells in mammalian development. Current opinion in cell biol-
36. Zou WW, Xiao HP, Gu MN, Liu KX, Liu ZQ. Propofol induces rat embryonic neural stem cell apopto-
35. Zou WW, Xiao HP, Gu MN, Liu KX, Liu ZQ. Propofol induces rat embryonic neural stem cell apopptosis
34. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
33. Fredriksson A, Ponten E, Gorth D, Eriksson P. Neonatal exposure to a combination of N-methyl-D-
aeptosis of hippocampal neurons in vitro via downregulation of NF-kappaB p65 and Bcl-2 and
32. Spahr-Schopfer I, Vutskits L, Toni N, Buchs PA, Parisi L, Muller D. Differential neurotoxic effects of pro-
31. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
30. Spahr-Schopfer I, Vutskits L, Toni N, Buchs PA, Parisi L, Muller D. Differential neurotoxic effects of pro-
29. Casati A, Fanelli G, Casaletti E, Cedrati V, Veglia F, Torri G. The target plasma concentration of propof-
28. Spahr-Schopfer I, Vutskits L, Toni N, Buchs PA, Parisi L, Muller D. Differential neurotoxic effects of pro-
27. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
26. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
25. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
24. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
23. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
22. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
21. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
20. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
19. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
18. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
17. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
16. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
15. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
14. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
13. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
12. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
11. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
10. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
9. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
8. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
7. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
6. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
5. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
4. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
3. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
2. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
1. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
0. Fredriksson A, Ponten E, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neur-
upregulation of caspase-3. Cell biochemistry and function. 2014; 32(8):720–9. doi: 10.1002/cbf.3077 PMID: 25431245.

54. Twaroski DM, Yan Y, Zaja I, Clark E, Bosnjak ZJ, Bai X. Altered Mitochondrial Dynamics Contributes to Propofol-induced Cell Death in Human Stem Cell-derived Neurons. Anesthesiology. 2015; 123 (5):1067–83. doi: 10.1097/ALN.0000000000000857 PMID: 26352374; PubMed Central PMCID: PMC4632973.

55. Dong C, Rovnaghi CR, Anand KJ. Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells. Crit Care Med. 2012; 40(8):2407–16. doi: 10.1097/CCM.0b013e318253563c PMID: 22635046; PubMed Central PMCID: PMC3507476.

56. Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med. 2003; 348(21):2110–24. Epub 2003/05/23. doi: 10.1056/NEJMra021261 348/21/2110 [pii]. PMID: 12761368.

57. Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Current medicinal chemistry. 2000; 7(2):249–71. PMID: 10637364.

58. Lee IH, Culley DJ, Baxter MG, Xie Z, Tanzi RE, Crosby G. Spatial memory is intact in aged rats after propofol anesthesia. Anesth Analg. 2008; 107(4):1211–5. doi: 10.1213/ane.0b013e31817ee879 PMID: 18806209.

59. Brann JH, Firestein SJ. A lifetime of neurogenesis in the olfactory system. Frontiers in neuroscience. 2014; 8:182. doi: 10.3389/fnins.2014.00182 PMID: 25018689; PubMed Central PMCID: PMC4071289.

60. Drew LJ, Fusi S, Hen R. Adult neurogenesis in the mammalian hippocampus: why the dentate gyrus? Learning & memory. 2013; 20(12):710–29. doi: 10.1101/lm.026542.112 PMID: 24255101; PubMed Central PMCID: PMC3834622.

61. Sakamoto M, Ieki N, Miyoshi G, Mochimaru D, Miyachi H, Imura T, et al. Continuous postnatal neurogenesis contributes to formation of the olfactory bulb neural circuits and flexible olfactory associative learning. J Neurosci. 2014; 34(17):5788–99. doi: 10.1523/JNEUROSCI.0674-14.2014 PMID: 24760839.

62. Culley DJ, Baxter MG, Yukhananov R, Crosby G. Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. Anesthesiology. 2004; 100(2):309–14. Epub 2004/01/24. 00000542-200402000-00020 [pii]. PMID: 14739805.

63. Shyr MH, Tsai TH, Tan PP, Chen CF, Chan SH. Concentration and regional distribution of propofol in brain and spinal cord during propofol anesthesia in the rat. Neuroscience letters. 1995; 184(3):212–5. PMID: 7715849.

64. Shyr MH, Tsai TH, Yang CH, Chen HM, Ng HF, Tan PP. Propofol anesthesia increases dopamine and serotonin activities at the somatosensory cortex in rats: a microdialysis study. Anesth Analg. 1997; 84 (6):1344–8. PMID: 9174318.